SecBot SecBot

Prescription Pricing for the People Act of 2025

S. 527 Sen. Chuck Grassley (R-IA) In committee
Bill text PDF
  1. Introduced Feb 11
  2. Committee Feb 11
  3. Passed Senate Next
  4. Passed House Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Feb 11, 2025Next: Senate vote
565d ago Apr 10, 2025: Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
2companies, 8 filings
Subscribe to see spend
Member trades
0trades in the last 90 days
None in these companies
Who the bill helps and hurts Subscribe

Companies lobbying on this bill

2 companies
Companies by sector
Biotech & Pharma 2
Search all 2 companies, their asks and price moves Subscribe

Summary

Prescription Pricing for the People Act of 2025

Full summary4 paragraphs

This bill requires the Federal Trade Commission (FTC) to report about anticompetitive practices and other trends within the pharmaceutical supply chain that may impact the cost of prescription drugs.

The report must address whether pharmacy benefit managers (PBMs) (1) reimburse pharmacies owned by the PBM at a higher price than other pharmacies, and (2) implement formulary designs to increase the market share of higher-cost prescription drugs or depress the market share of lower-cost prescription drugs.

The FTC also must provide recommendations to increase transparency in the supply chain, prevent anticompetitive practices, and ensure that consumers benefit from cost savings or efficiencies that result from mergers and consolidations.

Additionally, the FTC must report the number and nature of complaints the FTC receives relating to an allegation of anticompetitive conduct by a manufacturer of a sole-source drug.

Library of Congress summary, Feb 11, 2025

Summary versions
  • Introduced in SenateFeb 11, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 27, 2026.